Paper40968428
Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.
Kumar SLS and 4 others. Mini Rev Med Chem, 2025. Cited by 0 papers, by iCite.
Cite this record
ConductScience Library. Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes. Papers, record 40968428. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/40968428
- Sources
- 11 sources
- Release
- papers-2026-11-12-0.1.0
Paper
PubMed's record of the paper, with iCite's citation figures. No abstract is shown.
- Title
- Therapeutic Potential of Underexplored Phytoconstituents Targeting Molecular Pathways in Breast Cancer Subtypes.
- PubMed
Topics7
NLM's MeSH indexing of the paper, its major topics first.
| MeSH term | Major |
|---|---|
| Breast Neoplasms | Major topic |
| Antineoplastic Agents, Phytogenic | Major topic |
| Phytochemicals | Major topic |
| Humans | |
| Female | |
| Signal Transduction | |
| Animals |
Source PubMed
References127
The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.
| Order | PMID | Title | Journal | Year | In Papers | Source |
|---|---|---|---|---|---|---|
| 1 | 38572751 | Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. | CA Cancer J Clin | 2024 | https://conductscience.org/library/papers/38572751 | PubMed |
| 2 | 36185256 | Epigenetics and environment in breast cancer: New paradigms for anti-cancer therapies. | Front Oncol | 2022 | https://conductscience.org/library/papers/36185256 | PubMed |
| 3 | 16175185 | Clinical characteristics of different histologic types of breast cancer. | Br J Cancer | 2005 | https://conductscience.org/library/papers/16175185 | PubMed |
| 4 | 29593010 | Differences in Breast Cancer Survival by Molecular Subtypes in the United States. | Cancer Epidemiol Biomarkers Prev | 2018 | https://conductscience.org/library/papers/29593010 | PubMed |
| 5 | 34924252 | Unmet challenges in systemic therapy for early stage breast cancer. | Breast | 2022 | https://conductscience.org/library/papers/34924252 | PubMed |
| 6 | 35437454 | Anti-breast cancer effects of phytochemicals: primary, secondary, and tertiary care. | EPMA J | 2022 | https://conductscience.org/library/papers/35437454 | PubMed |
| 7 | 35892331 | Molecular Biomarkers in Cancer. | Biomolecules | 2022 | https://conductscience.org/library/papers/35892331 | PubMed |
| 8 | 31776839 | Grading Ductal Carcinoma In Situ (DCIS) of the Breast - What's Wrong with It? | Pathol Oncol Res | 2020 | https://conductscience.org/library/papers/31776839 | PubMed |
| 9 | 37542814 | Imaging biomarkers are underutilised but highly predictive prognostic factors for the more fatal breast cancer subtypes. | Eur J Radiol | 2023 | https://conductscience.org/library/papers/37542814 | PubMed |
| 10 | 38563878 | Unveiling the pharmacological potential of plant triterpenoids in breast cancer management: an updated review. | Naunyn Schmiedebergs Arch Pharmacol | 2024 | https://conductscience.org/library/papers/38563878 | PubMed |
| 11 | 17728712 | Mechanisms of disease: angiogenesis and the management of breast cancer. | Nat Clin Pract Oncol | 2007 | https://conductscience.org/library/papers/17728712 | PubMed |
| 12 | 37169756 | Angiogenic signaling pathways and anti-angiogenic therapy for cancer. | Signal Transduct Target Ther | 2023 | https://conductscience.org/library/papers/37169756 | PubMed |
| 13 | 35281942 | Targeting Angiogenesis in Breast Cancer: Current Evidence and Future Perspectives of Novel Anti-Angiogenic Approaches. | Front Pharmacol | 2022 | https://conductscience.org/library/papers/35281942 | PubMed |
| 14 | 33489906 | The Metabolic Mechanisms of Breast Cancer Metastasis. | Front Oncol | 2020 | https://conductscience.org/library/papers/33489906 | PubMed |
| 15 | 25489583 | Circulating tumor cells and epithelial, mesenchymal and stemness markers: characterization of cell subpopulations. | Ann Transl Med | 2014 | https://conductscience.org/library/papers/25489583 | PubMed |
| 16 | 20029421 | Integrins in cancer: biological implications and therapeutic opportunities. | Nat Rev Cancer | 2010 | https://conductscience.org/library/papers/20029421 | PubMed |
| 17 | 33974235 | Luminal Breast Cancer: Risk of Recurrence and Tumor-Associated Immune Suppression. | Mol Diagn Ther | 2021 | https://conductscience.org/library/papers/33974235 | PubMed |
| 18 | 38487526 | The cellular composition of the tumor microenvironment is an important marker for predicting therapeutic efficacy in breast cancer. | Front Immunol | 2024 | https://conductscience.org/library/papers/38487526 | PubMed |
| 19 | 33777750 | The Crosstalk Between Tumor Cells and the Immune Microenvironment in Breast Cancer: Implications for Immunotherapy. | Front Oncol | 2021 | https://conductscience.org/library/papers/33777750 | PubMed |
| 20 | 36629385 | RISING STARS: Hormonal regulation of the breast cancer microenvironment. | J Mol Endocrinol | 2023 | https://conductscience.org/library/papers/36629385 | PubMed |
Genes2
The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.
| Gene | NCBI Gene ID | Linked by | In Genes | Source |
|---|---|---|---|---|
| ERBB2 | 2064 | PubTator's text mining | https://conductscience.org/library/genes/2064 | NCBI Gene |
| NR4A1 | 3164 | PubTator's text mining | https://conductscience.org/library/genes/3164 | NCBI Gene |
Data dates
The date of each source this release read.
- Trials
- 2026-11-12
- Gene search
- 2026-11-11
- Pipelines
- 2026-09-18
None in this release
- Grants
- Trials
- Comments and corrections
- Cited by
- Drugs
- Data
Sources 11
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- HGNCCC0
- iCiteCC BY 4.0
- NCBI GenePublic domain (US government)
- NIH RePORTER's grant and paper linksPublic domain
- Open TargetsCC0 1.0
- PMC's ID filePublic domain (US government)
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0
Each source's terms
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- HGNCCC0: https://www.genenames.org/about/license/
- iCiteCC BY 4.0
- NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
- PubMedNLM's terms
- PubTator 3Public domain
- UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this paper from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/papers/v1/40968428
GET https://conductscience.org/api/papers/v1/40968428/references?page=2